Todd C. Davis - Dec 5, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Todd C. Davis
Stock symbol
LGND
Transactions as of
Dec 5, 2022
Transactions value $
$0
Form type
4
Date filed
12/6/2022, 07:25 PM
Previous filing
Aug 8, 2022
Next filing
Dec 27, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Award $0 +132K $0.00 132K Dec 5, 2022 Common Stock 132K $69.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from the date of grant, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after the date of grant and the remaining stock options vesting in 42 equal monthly installments thereafter.